Cidara Therapeutics Inc (CDTX) announced its most recent quarterly financial results on Wednesday, Mar-15-2017. CDTX reported $-0.88 earnings per share for the quarter, missing the analyst consensus estimate by $-0.11. Analysts had a consensus of $-0.77. During the same quarter in the previous year, the company posted $-0.72 EPS.
Based on several research reports , Shares were Reiterated by H.C. Wainwright on Feb 22, 2017 to “Buy” and Lowered the Price Target to $ 18 from a previous price target of $25 .WBB Securities Upgraded Cidara Therapeutics Inc on Feb 22, 2017 to ” Hold”, Price Target of the shares are set at $7.25.Cidara Therapeutics Inc was Resumed by Leerink Partners to “Outperform” on Dec 21, 2016. H.C. Wainwright Initiated Cidara Therapeutics Inc on Dec 19, 2016 to “Buy”, Price Target of the shares are set at $25.
Several company insiders have filed Insider transactions , on May 23, 2016, Kevin Forrest (CFO) purchased 4,356 shares at $11.53 per share price. According to the SEC, on May 23, 2016, Jeffrey Stein (CEO) purchased 4,310 shares at $11.51 per share price. On Apr 22, 2015, Nina S Kjellson (director) purchased 200,000 shares at $16.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Cidara Therapeutics Inc opened for trading at $7 and hit $7.35 on the upside on Wednesday, eventually ending the session at $7.35, with a gain of 5.76% or 0.4 points. The heightened volatility saw the trading volume jump to 49,363 shares. Company has a market cap of $123 M.
Cidara Therapeutics Inc. formerly K2 Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery development and commercialization of anti-infective products. The Company’s products are the formulations of its compound CD101 which is an echinocandin. Its products include CD101 intravenous (biafungin) and CD101 topical (topifungin). In addition it owns an immunotherapy technology platform Cloudbreak. The Company is also developing other candidates for the treatment of bacterial and viral infections. CD101 IV and CD101 topical are in early stage of preclinical development. The Company’s Cloudbreak development candidates includeC001 and C016. It has conducted preclinical studies to evaluate the tolerability toxicity and pharmacokinetic profile of C001 in mice and guinea pigs. Cloudbreak development candidates have demonstrated preclinical proof-of-principle efficacy and safety in preclinical studies.